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SUMMARY
Objectives. This study is part of a programme on 
reduction of postpartum haemorrhage (PPH). 
Ergometrine and methylergometrine have a 
favourable effect on both blood loss and maternal 
morbidity and mortality and oral preparations 
were regarded as a possible treatment for use 
in tropical countries. The stability of oral prepa­
rations of the two ergometrine compounds 
under tropical conditions was unknown and was 
therefore examined in this study.
Study methods, The 'experimental shelf lives' 
of ergometrine and methylergometrine tablets 
were examined by exposing the tablets to seven 
artificially controlled conditions. Samples were 
analysed by high performance liquid chromatog­
raphy at nine different sampling times over a 
period of 1 year to determine the content of 
ergometrine and methylergometrine.
Results. Under refrigeration (test I), less than 
90% of the stated amount of active ingredient 
was found in the tablets after 14 weeks in the 
case of ergometrine and 21 weeks in the case of 
methylergometrine. When stored in the dark 
at 40°C and 75% relative humidity (test VI), 
the tablets fall outside accepted specification 
(=90-110%  of state amount of active ingredient) 
within 3 weeks in the case of ergometrine and 21 
weeks in the case of coated methylergometrine 
tablets. The stability of uncoated ergometrine 
tablets was far less than that of coated methyl­
ergometrine tablets. Instability worsened under 
extreme humid conditions (test IV and VI), and 
hot conditions (test V), for both ergometrine
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and methylergometrine. From week 31 onwards 
the coating did not seem to protect the com­
pound anymore, irrespective of the condition of 
exposure.
Conclusions. Tropical conditions make the 
tablets unstable with humidity as the main adverse 
factor. The sugar-coated methylergometrine tab­
lets are more stable under humid/hot conditions 
than the non-coated ergometrine tablets. Under all 
simulated conditions both oral ergometrine and 
methylergometrine tablets are unstable.
INTRO DUCTIO N
Postpartum haemorrhage (PPH) is still one of the 
most common causes of maternal death, especially in 
third world countries (I—3). As in these countries 
emergency referral in case of severe bleeding is 
difficult to arrange, prevention and management of 
PPH at all levels of obstetric care is mandatory. For 
prevention and management of PPH, the routine use 
of oxytocics in the postpartum period is advocated (4). 
Drugs have to be stable to be used in tropical climates 
and the route of administration should be simple when 
used by untrained people.
The route of choice is by mouth. Among all 
oxytocic drugs only the scale alkaloids are suitable for 
oral administration. Therefore, oral ergometrine and 
methylergometrine with favourable effects on both 
blood loss and maternal morbidity and mortality were 
regarded as possible treatments for use in tropical 
countries.
Manufacturers usually do not investigate the 
stability of preparations under tropical conditions. 
They usually perform their tests in temperate climates. 
In third world countries, it is often practically and/or 
economically not possible to protect pharmaceutical
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preparations from the harmful effects of high tempera­
tures and high relative humidity during transportation, 
storage and use. Recent stability studies of both 
ergometrine and methylergometrine injectable solu­
tions showed high extents of deterioration upon 
exposure to elevated temperatures and to light (5—7). 
Moreover, the formulation seems to be more impor­
tant than whether ergometrine or methylergometrine 
is used (8).
The aim of this investigation was to examine the 
stability of ergometrine and methylergometrine tablets 
to determine whether it was feasible to replace the 
parenteral route of oxytocics by orally administered 
drugs. The stability of the compounds have been 
assessed by using 'experimental shelf life' methodol­
ogy to demonstrate whether the drugs can be 
transported and stored without loss of potency.
MATERIAL AND M ETH O D S 
Study design
Definitions used in the study are given in Table 1 . 
In the design of this study the recommendations 
laid down in the Protocol of the Research of the 
Stability of Drugs in Aqueous Solutions by the Dutch 
Society of Hospital Pharmacists (9) have been used. 
We simulated seven tropical conditions (Table 2). 
Taking into account the known vulnerability of 
ergometrine and methylergometrine on exposure 
to light, all tablets were tested for light-induced 
degradation (10).
The following tablets were examined: ergometrine 
maleate, 0*2 mg tablets, BP88, batch number 91 I 
02/590E and containing 147 \Xg  free base, and 
methylergometrine maleate, 0-125 mg tablets, batch
Stability
Table 1. Definitions used in study
Batch 
Shelf life
Experimental shelf life
Pharmaceutical requirements
The extent to which a product retains, within 
specified limits, and throughout its period of 
storage and use (i.e. its shelf life), the same 
properties and characteristics it possessed at the 
time of its manufacture (Ref. 21)
A homogeneously produced number of drugs 
The time during which at least 90% of the declared 
dose of the active ingredient is still present in the 
product (f-90 or time for 10% loss of active 
ingredient) (Refs 20, 22)
The period of time during which under defined 
experimental conditions a batch fulfils the 
requirements (Ref. 10)
The level of active ingredient has to be within 
90—110% of the stated amount to fulfil the 
pharmaceutical requirements (Ref, 21)
Storage condition
Test Light exposure Temperature Relative humidity Notation
Table 2. Definitions of simulated 
tropical conditions
I Dark 6-10°C 83-85%: ambient D6/83
II Dark 20°C* 75 %t D20175
III Dark 30°C* 45%+ D 3 0/45
IV Dark 30°C* 75%+ D 30/75
V Dark 40°C* 12—28%: ambient D40/25
VI Dark 40°C* 75%** D40/75
VII Lights 20-25-Cg 20—35%: ambient L20/30
^Specified within dr 2°G 
tSpecified within ±  5%.
^Fluorescent white light, 450-Ó50 nm; 
1000 lx.
§Room temperature.
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number 2003, 95 \ig free base. Tablets were received 
in closed tins. During the storage tests the tablets were 
exposed to the intended conditions, in identical trans­
parent tins. Each tin contained four tablets. For each 
sampling period (weeks 0-52), a different tin was used. 
One batch from each manufacturer was examined. To 
achieve acceptable statistical power, four tablets were 
assayed per storage condition per manufacturer. At 
weeks 0 and 52, 20 tablets per storage condition 
per manufacturer were investigated. Tablet weight, 
integrity and colour were assessed prior to assay of 
drug content.
Assay method
High performance/pressure liquid chromatography 
(HPLC) was used in preference to a radio­
immunoassay because of its stability-indicating 
properties despite its lower sensitivity relative to the 
latter (11—15). The column was 25 cm X 4*6 mm ID 
packed with Spherisorb 5-ODS (particle size 5 |im; 
Chrompack, Middelburg, Netherlands) with a guard 
column (75 mm X 2*1 mm ID) packed with 10 |im 
pellicular reversed phase (Chrompack, catalogue no.
028653). An injection loop of 100 jul was used. The 
mobile phase consisted of a mixture of acetonitrile as 
solvent A and 0*067 M monobasic KH2PO4:0*05% 
diethyl amine H20  buffer as solvent B. The mixture 
consisted of 60% of A and 40% of B. All reagents were 
of analytical grade (Merck, Darmstadt, Germany). The 
flow rate was 1-2 ml/min. Detection wavelength was 
240 nm. The retention time was 6*8 min, the capacity 
factor was 3*24; the analysis was carried out at room 
temperature. The detection limit of ergometrine and 
methylergometrine in water was 0*55 ng, both at a 
signal to noise ratio of 1:3. The intra-day variation was 
1 *2% for ergometrine and 2*2% for methylergometrine 
and the inter-day variation was 1*73% for ergometrine 
and 5*07% for methylergometrine.
The data were analysed using a general linear model 
and a logistic regression model for ordinal response 
variables.
RESULTS
The raw data are published in the World Health 
Organization/Drug Action Programme Research 
Series (15). At T = 0, the initial drug content of 20s 
tablets of each brand fulfilled the pharmaceutical
Time (weeks)
Fig. 1. Stability of oral ergometrine and methylergo­
metrine exposed to least (I) and most (VI) extreme condi­
tions. E, ergometrine; ME, methylergometrine; D6/83, test I: 
6°C, 83% relative humidity and darkness; D40/75 test VI: 
40 °C, 75% relative humidity and darkness.
requirements. The results of test I (least extreme 
condition) and test VI (most extreme condition) for 
both ergometrine and methylergometrine tablets are 
shown in Fig. 1 .
Ergometrine
Active ingredient, The level of active ingredient in the 
product declines when stored under all conditions 
studied. Under refrigerated storage (D6/83), the least 
extreme condition, ergometrine remained stable for 3 
weeks (content was 100*7% of stated amount; 
0*148 ±  0*014 mg/tablet) but at 7 weeks only 85*1% 
(0*125 ±  0*005 mg/tablet) of the stated amount 
remained. W hen stored at 40°C and 75% relative 
humidity in the darkness (D40/75), the most extreme 
condition, ergometrine was unstable with only 26*5% 
(0*039 =t 0*008 mg/tablet) of the stated amount left 
after 3 weeks, and < 1 %  (0*001 ±  0-001 mg/tablet) 
after 52 weeks of exposure (Fig. 1 ).
The influence of humidity was shown in the 
combination of test IV (D30/75), very humid, and 
test V (D40/25), h o t and dry. A t 30°C and 75% 
relative humidity in the darkness (D30/75), only 
23% (0*034 ±  0*002 mg/tablet) of the stated
©  1995 Blackwell Science Ltd, Journal of Clinical Pharmacy and TherapeulicSj 20 , 109-113
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amount remained after 21  weeks. At 40°C and 
25% relative humidity in the darkness (D40/25), 
44-9% (0*066 ±  0*010 m g/t ablet) of the stated 
amount was left after 52 weeks. In these tests 
humidity had a greater influence on stability than 
temperature.
The influence of light was shown in test II (D 20/75) 
and test VII (L20/30). At 3 weeks of exposure the 
influence of light was stronger than that of humidity 
with only 61*2% (0*090 0*010 mg/tablet) of the 
stated amount left (test VII), whereas in test II 70*7% 
(0-104 ±  0*008 mg/tablet) of the stated amount was 
still left. However, over a period of a year the 
influence of light was weaker than that of humidity, 
showing only 15*6% at 52 weeks in test II (D20/75) 
and 44*2% in test VII (L20/30).
Methylergo metrine
The drug was unstable under all conditions studied. 
Under refrigerated storage (Dó/83), the least extreme 
condition, methylergometrine was stable for 21  weeks 
(92*6% of stated amount; 0*088 i  0*003 mg/tablet) but 
after 30 weeks it no longer fulfilled the pharmaceutical 
requirements (52*6%; 0*050 ±  0*002 mg/tablet). At 
40°C find 75% relative humidity in the dark (D40/75), 
the most extreme condition, the methylergometrine 
product was unstable, with 63*2% (0*060 ±  0*003 mg/ 
tablet) of the stated amount left after 21 weeks, 
and <50%  (0*040 dt 0*002 mg/tablet) after 52 weeks
(Fig. 1 ).
Hardly any difference was seen between the results 
of test IV (D30/75) and test V (D40/25), with, respec­
tively, 49*5% (0*047 ±  0*003 mg/tablet) and 51*6% 
(0*049 ±  0*002 mg/tablet) of drug left after 52 weeks 
of exposure.
Under all conditions, the uncoated ergometrine 
tablets were far less stable than the coated methyl­
ergometrine ones. Instability rises with humidity 
(D30/75 or D40/75) and temperature (D40/25), for 
both ergometrine and methylergometrine. In the least 
extreme condition the coating did not seem to protect 
the compounds anymore from week 31 onwards
(Fig. 1 ).
No differences in weight larger than 0*1 m g were 
noticed. Discolouration occurred in the tablets espe­
cially when stored under humid conditions. Growth of 
mould was observed on some tablets stored in humid 
conditions (tests II, IV and VI).
DISCUSSION
Tablets
Drug stability is dependent on many product-related 
factors (16,17), i.e. the active ingredient, the excipients, 
the dosage form, the manufacturing process and the 
nature of the packaging. Methylergometrine tablets 
were included in our investigation because of the 
claims that methylergometrine shows less hyperten­
sive side effects and less influence on postpartum 
prolactin levels than ergometrine (18,19). When 
supplied by Unicef, methylergometrine tablets are as 
cheap as ergometrine. The choice of manufacturer was 
dependent on the availability of their products. 
Although ergometrine and methylergometrine are 
supposedly being produced on market demand', in 
practice they are produced only once a year. Only one 
batch was available from each manufacturer. As only 
one brand of ergometrine and methylergometrine are 
generally distributed, comparison between brands as 
recommended by Hogerzeil et al. (8) was not possible 
in this study.
Sampling points in time
Long-term stability studies under 'temperate climate' 
conditions normally last 5 years (10). The tablets in 
this study have been subjected to conditions that are 
more extreme. A shorter period of investigation has 
been accepted, as deterioration of tablet quality will 
appear sooner. The stability test was performed for a 
period of 1 year only as in actual practice in tropical 
countries tablets should not be stored after opening of 
the box for longer periods. Loss of potency by water 
absorption was expected to occur early (20). There­
fore, the sampling was done more frequently during 
the early stages and eight samplings were done over 
the first 21 weeks (9).
Under the least harmful storage conditions (D6/83) 
ergometrine and methylergometrine were not stable 
for more than 7 and 21 weeks, respectively. The 
results are alarming, indicating that careful storage of 
those products is critical when used under tropical 
conditions. Refrigerated storage may be necessary. 
Protecting the tablets from humidity by coating or 
special packaging may help, as humidity seems to be 
more harmful than temperature. Light is not as dam­
aging on tablets as on ampoules of the drugs (2 1 ). 
f Methylergomerine is substantially more stable than 
ergometrine even under test VI (D40/75).
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CONCLUSIONS AND RECOMMENDATIONS
Both ergometrine and methylergometrine tablets are 
not stable under simulated tropical conditions. These 
tablets are the only oxytocic drugs given by mouth 
and therefore easy to administer when used by 
untrained people. However, because of their strong 
instability under the conditions studied, those prepa­
rations are not suitable for use as prophylactic agents 
of PPH. Moreover, pharmacokinetic data suggest that 
their absorption is also unreliable (23).
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